Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Spectrum and functional validation of PSMB5 mutations in multiple myeloma.

Barrio S, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H, Kortüm KM.

Leukemia. 2018 Jul 19. doi: 10.1038/s41375-018-0216-8. [Epub ahead of print]

PMID:
30026573
2.

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Merz M, Hielscher T, Hoffmann K, Seckinger A, Hose D, Raab MS, Hillengass J, Jauch A, Goldschmidt H.

Leukemia. 2018 Jul 6. doi: 10.1038/s41375-018-0202-1. [Epub ahead of print] No abstract available.

PMID:
29977018
3.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G.

Leukemia. 2018 Jul 2. doi: 10.1038/s41375-018-0196-8. [Epub ahead of print]

PMID:
29967379
4.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia. 2018 Jun 29. doi: 10.1038/s41375-018-0195-9. [Epub ahead of print] No abstract available.

PMID:
29959413
5.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ.

Blood. 2018 Jun 8. pii: blood-2018-03-840132. doi: 10.1182/blood-2018-03-840132. [Epub ahead of print]

PMID:
29884741
6.

Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.

Lehners N, Ellert E, Xu J, Hillengass J, Leichsenring J, Stenzinger A, Goldschmidt H, Andrulis M, Raab MS.

Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1443450. [Epub ahead of print]

PMID:
29616856
7.

A systematic classification of death causes in multiple myeloma.

Mai EK, Haas EM, Lücke S, Löpprich M, Kunz C, Pritsch M, Knaup-Gregori P, Raab MS, Schlenzka J, Bertsch U, Hillengass J, Goldschmidt H.

Blood Cancer J. 2018 Mar 8;8(3):30. doi: 10.1038/s41408-018-0068-5. No abstract available.

8.

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

Breitkreutz I, Podar K, Figueroa-Vazquez V, Wilhelm S, Hayden PJ, Anderson KC, Raab MS.

Ann Hematol. 2018 May;97(5):839-849. doi: 10.1007/s00277-018-3237-5. Epub 2018 Jan 23.

PMID:
29359239
9.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

10.

Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response.

Lehners N, Becker N, Benner A, Pritsch M, Löpprich M, Mai EK, Hillengass J, Goldschmidt H, Raab MS.

Cancer Med. 2018 Feb;7(2):307-316. doi: 10.1002/cam4.1283. Epub 2017 Dec 28.

11.

Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.

Baertsch MA, Hundemer M, Hillengass J, Goldschmidt H, Raab MS.

Hematol Oncol. 2018 Feb;36(1):258-261. doi: 10.1002/hon.2473. Epub 2017 Aug 25.

PMID:
28840598
12.

Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in Cancer.

Cosenza MR, Cazzola A, Rossberg A, Schieber NL, Konotop G, Bausch E, Slynko A, Holland-Letz T, Raab MS, Dubash T, Glimm H, Poppelreuther S, Herold-Mende C, Schwab Y, Krämer A.

Cell Rep. 2017 Aug 22;20(8):1906-1920. doi: 10.1016/j.celrep.2017.08.005.

13.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
14.

Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.

Baertsch MA, Hillengass J, Blocka J, Schönland S, Hegenbart U, Goldschmidt H, Raab MS.

Hematol Oncol. 2018 Feb;36(1):210-216. doi: 10.1002/hon.2462. Epub 2017 Jul 7.

PMID:
28685863
15.

Extracellular vesicles mediate intercellular communication: Transfer of functionally active microRNAs by microvesicles into phagocytes.

Claßen L, Tykocinski LO, Wiedmann F, Birr C, Schiller P, Tucher C, Krienke S, Raab MS, Blank N, Lorenz HM, Schiller M.

Eur J Immunol. 2017 Sep;47(9):1535-1549. doi: 10.1002/eji.201646595. Epub 2017 Jul 20.

PMID:
28665018
16.

Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.

Merz M, Raab MS, Goldschmidt H, Hillengass J.

J Cancer Res Clin Oncol. 2017 Dec;143(12):2521-2526. doi: 10.1007/s00432-017-2463-x. Epub 2017 Jun 26.

PMID:
28653099
17.

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.

Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehners N, Penzel R, Weichert W, Ho AD, Schirmacher P, Goldschmidt H, Andrulis M, Raab MS.

Oncogenesis. 2017 May 15;6(5):e337. doi: 10.1038/oncsis.2017.36.

18.

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H, Hillengass J.

Haematologica. 2017 Aug;102(8):1432-1438. doi: 10.3324/haematol.2017.168005. Epub 2017 May 11.

19.

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.

Natoni A, Smith TAG, Keane N, McEllistrim C, Connolly C, Jha A, Andrulis M, Ellert E, Raab MS, Glavey SV, Kirkham-McCarthy L, Kumar SK, Locatelli-Hoops SC, Oliva I, Fogler WE, Magnani JL, O'Dwyer ME.

Leukemia. 2017 Dec;31(12):2642-2651. doi: 10.1038/leu.2017.123. Epub 2017 Apr 25.

20.

Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability.

Petersen AB, Andersen NS, Konotop G, Hanafiah NH, Raab MS, Krämer A, Clausen MH.

Eur J Med Chem. 2017 Apr 21;130:240-247. doi: 10.1016/j.ejmech.2017.02.055. Epub 2017 Feb 22.

PMID:
28258034
21.

Oxygen bubbles to predict sensitivity to IMiDs.

Raab MS.

Blood. 2017 Feb 23;129(8):923-925. doi: 10.1182/blood-2017-01-760512. No abstract available.

22.

Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization.

Konotop G, Bausch E, Nagai T, Turchinovich A, Becker N, Benner A, Boutros M, Mizuno K, Krämer A, Raab MS.

Cancer Res. 2016 Nov 15;76(22):6690-6700. doi: 10.1158/0008-5472.CAN-16-1144. Epub 2016 Sep 13.

23.

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.

Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J.

Am J Hematol. 2016 Nov;91(11):E473-E477. doi: 10.1002/ajh.24533. Epub 2016 Sep 3.

24.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2016 Dec;101(12):e485-e487. Epub 2016 Aug 18. No abstract available.

25.

Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.

Krämer I, Engelhardt M, Fichtner S, Neuber B, Medenhoff S, Bertsch U, Hillengass J, Raab MS, Hose D, Ho AD, Goldschmidt H, Hundemer M.

Oncoimmunology. 2016 Feb 18;5(5):e1139662. doi: 10.1080/2162402X.2016.1139662. eCollection 2016 May.

26.

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

Kortüm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS.

Blood. 2016 Sep 1;128(9):1226-33. doi: 10.1182/blood-2016-02-698092. Epub 2016 Jul 25.

27.

Multiple myeloma: patient outcomes in real-world practice.

Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen P, Cavo M.

Br J Haematol. 2016 Oct;175(2):252-264. doi: 10.1111/bjh.14213. Epub 2016 Jul 13.

28.

Management of high-risk Myeloma: an evidence-based review of treatment strategies.

Lehners N, Hayden PJ, Goldschmidt H, Raab MS.

Expert Rev Hematol. 2016 Aug;9(8):753-65. doi: 10.1080/17474086.2016.1204908. Epub 2016 Jul 4. Review.

PMID:
27337562
29.

Multiple myeloma: practice patterns across Europe.

Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Schoen P, Yong K.

Br J Haematol. 2016 Oct;175(1):66-76. doi: 10.1111/bjh.14193. Epub 2016 Jun 13.

PMID:
27291397
30.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengaß J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H.

BMC Cancer. 2016 Apr 25;16:290. doi: 10.1186/s12885-016-2321-2.

31.

Strategies for improving the solubility and metabolic stability of griseofulvin analogues.

Petersen AB, Konotop G, Hanafiah NHM, Hammershøj P, Raab MS, Krämer A, Clausen MH.

Eur J Med Chem. 2016 Jun 30;116:210-215. doi: 10.1016/j.ejmech.2016.03.071. Epub 2016 Mar 28.

PMID:
27061984
32.

Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.

Mai EK, Benner A, Bertsch U, Brossart P, Hänel A, Kunzmann V, Naumann R, Neben K, Egerer G, Ho AD, Hillengass J, Raab MS, Neubauer A, Peyn A, Ko YD, Peter N, Scheid C, Goldschmidt H.

Br J Haematol. 2016 Jun;173(5):731-41. doi: 10.1111/bjh.13994. Epub 2016 Mar 17.

PMID:
26990892
33.

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.

Raab MS, Lehners N, Xu J, Ho AD, Schirmacher P, Goldschmidt H, Andrulis M.

Blood. 2016 Apr 28;127(17):2155-7. doi: 10.1182/blood-2015-12-686782. Epub 2016 Feb 16. No abstract available.

34.

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology.

Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Hillengass M, Wagner B, Hose D, Raab MS, Jauch A, Delorme S, Goldschmidt H, Weber MA, Hillengass J.

Eur Radiol. 2016 Nov;26(11):3939-3948. Epub 2016 Jan 15.

PMID:
26767378
35.

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S; 1703 study investigators.

Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16.

PMID:
26686406
36.

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.

Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A.

Haematologica. 2016 Mar;101(3):e116-9. doi: 10.3324/haematol.2015.136929. Epub 2015 Nov 26. No abstract available.

37.

Targeting the Pim kinases in multiple myeloma.

Keane NA, Reidy M, Natoni A, Raab MS, O'Dwyer M.

Blood Cancer J. 2015 Jul 17;5:e325. doi: 10.1038/bcj.2015.46. Review.

38.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3.

39.

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S.

Leuk Lymphoma. 2015;56(12):3320-8. doi: 10.3109/10428194.2015.1030641. Epub 2015 May 15.

PMID:
25813205
40.

A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.

Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Raab MS, Hillengass M, Wagner B, Jauch A, Hose D, Weber MA, Delorme S, Goldschmidt H, Hillengass J.

Haematologica. 2015 Jun;100(6):818-25. doi: 10.3324/haematol.2015.124115. Epub 2015 Mar 20.

41.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H.

Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19.

PMID:
25787915
42.

Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.

Breitkreutz I, Becker N, Benner A, Kosely F, Heining C, Hillengass J, Egerer G, Ho AD, Goldschmidt H, Raab MS.

Hematol Oncol. 2016 Dec;34(4):200-207. doi: 10.1002/hon.2199. Epub 2015 Mar 18.

PMID:
25784529
43.

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.

Wagner V, Hose D, Seckinger A, Weiz L, Meißner T, Rème T, Breitkreutz I, Podar K, Ho AD, Goldschmidt H, Krämer A, Klein B, Raab MS.

Oncotarget. 2014 Nov 15;5(21):10237-50.

44.

T cell-based targeted immunotherapies for patients with multiple myeloma.

Wang L, Jin N, Schmitt A, Greiner J, Malcherek G, Hundemer M, Mani J, Hose D, Raab MS, Ho AD, Chen BA, Goldschmidt H, Schmitt M.

Int J Cancer. 2015 Apr 15;136(8):1751-68. doi: 10.1002/ijc.29190. Epub 2014 Sep 19. Review.

45.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.

Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S.

Leukemia. 2015 Mar;29(3):696-704. doi: 10.1038/leu.2014.236. Epub 2014 Aug 8.

PMID:
25102945
46.

Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.

Breitkreutz I, Heiss C, Perne A, Beimler J, Jäger D, Egerer G, Ho AD, Neben K, Zeier M, Goldschmidt H, Raab MS.

Bone Marrow Transplant. 2014 Nov;49(11):1371-5. doi: 10.1038/bmt.2014.165. Epub 2014 Aug 4.

PMID:
25089594
47.

Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma.

Merz M, Hielscher T, Wagner B, Sauer S, Shah S, Raab MS, Jauch A, Neben K, Hose D, Egerer G, Weber MA, Delorme S, Goldschmidt H, Hillengass J.

Leukemia. 2014 Sep;28(9):1902-8. doi: 10.1038/leu.2014.75. Epub 2014 Feb 18.

PMID:
24535407
48.

Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.

Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M, Hose D, Kunz C, Heiß C, Ho AD, Goldschmidt H, Hillengass J.

Ann Oncol. 2014 Jan;25(1):189-95. doi: 10.1093/annonc/mdt509.

PMID:
24356629
49.

Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization.

Andrulis M, Ellert E, Mandel U, Clausen H, Lehners N, Raab MS, Goldschmidt H, Schwartz-Albiez R.

Histopathology. 2014 May;64(6):799-806. doi: 10.1111/his.12330. Epub 2014 Jan 21.

PMID:
24251368
50.

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.

Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D.

J Clin Oncol. 2013 Dec 1;31(34):4325-32. doi: 10.1200/JCO.2012.48.4923. Epub 2013 Oct 21.

PMID:
24145347

Supplemental Content

Support Center